Clinical trial · no report yet · Phase 2/Phase 3
DIAL
De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction
- NCT05255302 ↗
- Recruiting
- Intergroupe Francophone de Cancerologie Thoracique
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 9 |
The trial
ClinicalTrials.gov- Official title
- A Phase II-III Randomized Trial Evaluating Maintenance Pembrolizumab (± Pemetrexed) Until Progression Versus Observation (± Pemetrexed) After 6 Months of Platinum-based Doublet Chemotherapy Plus Pembrolizumab Induction Treatment in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2/Phase 3
- Status
- Recruiting
- Conditions
- Metastatic NSCLC
- Interventions
- Pembrolizumab before randomization; Chemotherapy; Pemetrexed; Pembrolizumab after randomization
- Arms
- Arm A : control Arm · Active comparator
- Arm B : experimental arm · Experimental
- Enrollment
- 1,360 (estimated)
- Primary outcomes
- Phase II: 18-month overall survival (OS)
- Phase III: overall survival
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
- Start
- May 2, 2022
- Primary completion
- May 2025 (estimated)
- Results posted
- No
- Registry record
- NCT05255302 · updated Apr 1, 2025